ID

39051

Descripción

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02142049

Link

https://clinicaltrials.gov/show/NCT02142049

Palabras clave

Versiones (1)
  1. 24/11/19 24/11/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

24 de noviembre de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Diffuse Large B Cell Lymphoma Relapsed NCT02142049

Inglés

Eligibility Diffuse Large B Cell Lymphoma Relapsed NCT02142049

1 formularios  
Criteria
Descripción

Criteria

eastern cooperative oncology group (ecog) performance status of ≤2
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
pathologically confirmed relapsed/refractory dlbcl
Descripción

Diffuse large B-cell lymphoma recurrent | Diffuse large B-cell lymphoma refractory

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0855111
UMLS CUI [2]
C0855112
subjects must have ≥1 measurable disease site on ct scan (≥ 1.5 cm in longest dimension).
Descripción

Measurable Disease Site Quantity CT scan | Measurable Disease Longest Diameter CT scan

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1515974
UMLS CUI [1,3]
C1265611
UMLS CUI [1,4]
C0040405
UMLS CUI [2,1]
C1513041
UMLS CUI [2,2]
C0552406
UMLS CUI [2,3]
C0040405
adequate hepatic and renal function:
Descripción

Liver function | Renal function

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0232741
UMLS CUI [2]
C0232804
ast or alt ≤2.5 x uln
Descripción

Aspartate aminotransferase measurement | Alanine aminotransferase measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201899
UMLS CUI [2]
C0201836
serum creatinine ≤ 2.0 mg/dl or creatinine clearance ≥60 ml/min/1.73
Descripción

Creatinine measurement, serum | Creatinine clearance measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201976
UMLS CUI [2]
C0373595
bilirubin ≤1.5 x uln
Descripción

Serum total bilirubin measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1278039
adequate hematologic function:
Descripción

Hematologic function

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0221130
anc >1,000 cells/mm3
Descripción

Absolute neutrophil count

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0948762
platelets ≥75,000 cells/mm3
Descripción

Platelet Count measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032181
hemoglobin ≥8.0 g/dl
Descripción

Hemoglobin measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0518015
prothrombin time (pt) and activated partial thromboplastin time (aptt) must be
Descripción

Prothrombin time assay | Activated Partial Thromboplastin Time measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0033707
UMLS CUI [2]
C0030605
≤1.5 x the upper limit of the normal range (uln)
Descripción

ID.13

Tipo de datos

boolean

must be registered into the revlimid rems™program and be willing to comply with the requirements of revlimid rems™.
Descripción

Enrollment Revlimid Program Specified | Compliance behavior Revlimid Program Specified

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1516879
UMLS CUI [1,2]
C1135145
UMLS CUI [1,3]
C3484370
UMLS CUI [1,4]
C0205369
UMLS CUI [2,1]
C1321605
UMLS CUI [2,2]
C1135145
UMLS CUI [2,3]
C3484370
UMLS CUI [2,4]
C0205369
major exclusion criteria:
Descripción

Exclusion Criteria Major

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C0205164
known central nervous system lymphoma
Descripción

Central nervous system lymphoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0280803
any chemotherapy, external beam radiation therapy, or anti-cancer antibodies within 2 weeks
Descripción

Chemotherapy | External Beam Radiation Therapy | Antineoplastic Antibody

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C1517033
UMLS CUI [3]
C4329348
radio- or toxin-immunoconjugates within 10 weeks
Descripción

Radioimmunoconjugates | Toxin Immunoconjugates

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0243019
UMLS CUI [2,1]
C0040549
UMLS CUI [2,2]
C0243020
prior allogenetic stem cell (or other organ) transplant within 6 months or any evidence of active graft-versus-host disease or requirement for immunosuppressants within 28 days prior to first dose of study drug
Descripción

Allogeneic Stem Cell Transplantation | Organ Transplant | Graft-vs-Host Disease | Requirement Immunosuppressive Agents

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2242529
UMLS CUI [2]
C0029216
UMLS CUI [3]
C0018133
UMLS CUI [4,1]
C1514873
UMLS CUI [4,2]
C0021081
Volver a la parte superior de la página

Similar models

Eligibility Diffuse Large B Cell Lymphoma Relapsed NCT02142049

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of ≤2
boolean
C1520224 (UMLS CUI [1])
Diffuse large B-cell lymphoma recurrent | Diffuse large B-cell lymphoma refractory
Item
pathologically confirmed relapsed/refractory dlbcl
boolean
C0855111 (UMLS CUI [1])
C0855112 (UMLS CUI [2])
Measurable Disease Site Quantity CT scan | Measurable Disease Longest Diameter CT scan
Item
subjects must have ≥1 measurable disease site on ct scan (≥ 1.5 cm in longest dimension).
boolean
C1513041 (UMLS CUI [1,1])
C1515974 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0040405 (UMLS CUI [1,4])
C1513041 (UMLS CUI [2,1])
C0552406 (UMLS CUI [2,2])
C0040405 (UMLS CUI [2,3])
Liver function | Renal function
Item
adequate hepatic and renal function:
boolean
C0232741 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
ast or alt ≤2.5 x uln
boolean
C0201899 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
Creatinine measurement, serum | Creatinine clearance measurement
Item
serum creatinine ≤ 2.0 mg/dl or creatinine clearance ≥60 ml/min/1.73
boolean
C0201976 (UMLS CUI [1])
C0373595 (UMLS CUI [2])
Serum total bilirubin measurement
Item
bilirubin ≤1.5 x uln
boolean
C1278039 (UMLS CUI [1])
Hematologic function
Item
adequate hematologic function:
boolean
C0221130 (UMLS CUI [1])
Absolute neutrophil count
Item
anc >1,000 cells/mm3
boolean
C0948762 (UMLS CUI [1])
Platelet Count measurement
Item
platelets ≥75,000 cells/mm3
boolean
C0032181 (UMLS CUI [1])
Hemoglobin measurement
Item
hemoglobin ≥8.0 g/dl
boolean
C0518015 (UMLS CUI [1])
Prothrombin time assay | Activated Partial Thromboplastin Time measurement
Item
prothrombin time (pt) and activated partial thromboplastin time (aptt) must be
boolean
C0033707 (UMLS CUI [1])
C0030605 (UMLS CUI [2])
ID.13
Item
≤1.5 x the upper limit of the normal range (uln)
boolean
Enrollment Revlimid Program Specified | Compliance behavior Revlimid Program Specified
Item
must be registered into the revlimid rems™program and be willing to comply with the requirements of revlimid rems™.
boolean
C1516879 (UMLS CUI [1,1])
C1135145 (UMLS CUI [1,2])
C3484370 (UMLS CUI [1,3])
C0205369 (UMLS CUI [1,4])
C1321605 (UMLS CUI [2,1])
C1135145 (UMLS CUI [2,2])
C3484370 (UMLS CUI [2,3])
C0205369 (UMLS CUI [2,4])
Exclusion Criteria Major
Item
major exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C0205164 (UMLS CUI [1,2])
Central nervous system lymphoma
Item
known central nervous system lymphoma
boolean
C0280803 (UMLS CUI [1])
Chemotherapy | External Beam Radiation Therapy | Antineoplastic Antibody
Item
any chemotherapy, external beam radiation therapy, or anti-cancer antibodies within 2 weeks
boolean
C0392920 (UMLS CUI [1])
C1517033 (UMLS CUI [2])
C4329348 (UMLS CUI [3])
Radioimmunoconjugates | Toxin Immunoconjugates
Item
radio- or toxin-immunoconjugates within 10 weeks
boolean
C0243019 (UMLS CUI [1])
C0040549 (UMLS CUI [2,1])
C0243020 (UMLS CUI [2,2])
Allogeneic Stem Cell Transplantation | Organ Transplant | Graft-vs-Host Disease | Requirement Immunosuppressive Agents
Item
prior allogenetic stem cell (or other organ) transplant within 6 months or any evidence of active graft-versus-host disease or requirement for immunosuppressants within 28 days prior to first dose of study drug
boolean
C2242529 (UMLS CUI [1])
C0029216 (UMLS CUI [2])
C0018133 (UMLS CUI [3])
C1514873 (UMLS CUI [4,1])
C0021081 (UMLS CUI [4,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial